Blueprint Medicines
Focus: Blueprint Medicines is a public biotechnology company specializing in small molecule discovery for oncology, women's health, and dermatology, with a concentrated revenue base anchored by its lead kinase inhibitor AYVAKIT.
Profile data last refreshed 6h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
1
2 recent layoff filings (12 mo) — 265 affected
- 8/7/2026 — Cambridge, MA · 229 affected · Layoff
- 6/30/2026 — Fayette, KY · 36 affected · Layoff
Source: state DOL filings via Big Local News
Should You Work at Blueprint Medicines?
AI assessmentHigh-potential science platform undermined by post-acquisition restructuring and organizational turbulence; suitable only for candidates with risk tolerance and willingness to navigate integration uncertainty.
Why Work Here
- Focused oncology portfolio with AYVAKIT at peak revenue ($55M Part D spending) and clinical expansion into systemic mastocytosis and other kinase-driven cancers
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Help build intelligence for Blueprint Medicines
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.